136 related articles for article (PubMed ID: 15769637)
1. The role of interleukin-2 receptor alpha in cancer.
Kuhn DJ; Dou QP
Front Biosci; 2005 May; 10():1462-74. PubMed ID: 15769637
[TBL] [Abstract][Full Text] [Related]
2. Effect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling.
Tkaczuk J; Yu CL; Baksh S; Milford EL; Carpenter CB; Burakoff SJ; McKay DB
Am J Transplant; 2002 Jan; 2(1):31-40. PubMed ID: 12095053
[TBL] [Abstract][Full Text] [Related]
3. IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production.
McDyer JF; Li Z; John S; Yu X; Wu CY; Ragheb JA
J Immunol; 2002 Sep; 169(5):2736-46. PubMed ID: 12193748
[TBL] [Abstract][Full Text] [Related]
4. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Bielekova B; Catalfamo M; Reichert-Scrivner S; Packer A; Cerna M; Waldmann TA; McFarland H; Henkart PA; Martin R
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5941-6. PubMed ID: 16585503
[TBL] [Abstract][Full Text] [Related]
5. The fractional excretion of soluble interleukin-2 receptor-alpha is an excellent predictor of the interleukin-2 receptor-alpha status after treatment with daclizumab.
ter Meulen CG; Jacobs CW; Wetzels JF; Klasen IS; Hilbrands LB; Hoitsma AJ
Transplantation; 2004 Jan; 77(2):281-6. PubMed ID: 14742994
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of immunosuppression by the therapeutic antibody daclizumab.
Yang H; Wang J; Du J; Zhong C; Zhang D; Guo H; Guo Y; Ding J
Cell Res; 2010 Dec; 20(12):1361-71. PubMed ID: 20820193
[TBL] [Abstract][Full Text] [Related]
7. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events.
Goebel J; Stevens E; Forrest K; Roszman TL
Transpl Immunol; 2000 Nov; 8(3):153-9. PubMed ID: 11147695
[TBL] [Abstract][Full Text] [Related]
8. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
9. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
10. Direct inhibition of interleukin-2 receptor alpha-mediated signaling pathway induces G1 arrest and apoptosis in human head-and-neck cancer cells.
Kuhn DJ; Dou QP
J Cell Biochem; 2005 May; 95(2):379-90. PubMed ID: 15779002
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Mitchell DA; Cui X; Schmittling RJ; Sanchez-Perez L; Snyder DJ; Congdon KL; Archer GE; Desjardins A; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Reardon DA; Vredenburgh JJ; Bigner DD; Sampson JH
Blood; 2011 Sep; 118(11):3003-12. PubMed ID: 21768296
[TBL] [Abstract][Full Text] [Related]
12. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
Van Gelder T; Warlé M; Ter Meulen RG
Drugs; 2004; 64(16):1737-41. PubMed ID: 15301558
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation.
Koch M; Niemeyer G; Patel I; Light S; Nashan B
Transplantation; 2002 May; 73(10):1640-6. PubMed ID: 12042653
[TBL] [Abstract][Full Text] [Related]
14. Intracellular signaling consequences of anti-IL-2Ralpha blockade by daclizumab.
Tkaczuk J; Milford E; Yu C; Baksh S; Carpenter C; Burakoff S; McKay D
Transplant Proc; 2001; 33(1-2):212-3. PubMed ID: 11266783
[No Abstract] [Full Text] [Related]
15. Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability.
Kuhn DJ; Smith DM; Pross S; Whiteside TL; Dou QP
J Cell Biochem; 2003 Jul; 89(4):824-36. PubMed ID: 12858347
[TBL] [Abstract][Full Text] [Related]
16. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Waldmann TA
J Clin Immunol; 2007 Jan; 27(1):1-18. PubMed ID: 17216565
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.
Sampson JH; Schmittling RJ; Archer GE; Congdon KL; Nair SK; Reap EA; Desjardins A; Friedman AH; Friedman HS; Herndon JE; Coan A; McLendon RE; Reardon DA; Vredenburgh JJ; Bigner DD; Mitchell DA
PLoS One; 2012; 7(2):e31046. PubMed ID: 22383993
[TBL] [Abstract][Full Text] [Related]
18. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.
Berkowitz JL; Janik JE; Stewart DM; Jaffe ES; Stetler-Stevenson M; Shih JH; Fleisher TA; Turner M; Urquhart NE; Wharfe GH; Figg WD; Peer CJ; Goldman CK; Waldmann TA; Morris JC
Clin Immunol; 2014 Dec; 155(2):176-87. PubMed ID: 25267440
[TBL] [Abstract][Full Text] [Related]
19. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis.
Krueger JG; Walters IB; Miyazawa M; Gilleaudeau P; Hakimi J; Light S; Sherr A; Gottlieb AB
J Am Acad Dermatol; 2000 Sep; 43(3):448-58. PubMed ID: 10954656
[TBL] [Abstract][Full Text] [Related]
20. Scientists recall progress and promise of translational research.
Marwick C
J Natl Cancer Inst; 2001 Jan; 93(1):13-5. PubMed ID: 11136835
[No Abstract] [Full Text] [Related]
[Next] [New Search]
